Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease

Pathophysiology

Volumn 21, Issue 4, 2014, Pages 267-288

  Jones Hall, Yava L ^a   Grisham, Matthew B ^b  

^a PURDUE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

Author keywords

Colitis; Crohn's disease; Inflammatory bowel disease; Mouse model; Mouse pathology; Ulcerative colitis

Indexed keywords

INTERLEUKIN 10;

CLINICAL FEATURE; COMPARATIVE STUDY; CROHN DISEASE; ENTEROCOLITIS; GASTRITIS; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; ILEITIS; IMMUNOPATHOLOGY; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE TRANSFER; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 84912562037     PISSN: 09284680     EISSN: 1873149X     Source Type: Journal    
DOI: 10.1016/j.pathophys.2014.05.002     Document Type: Review

References (195)

1. Longobardi T., Jacobs P., Bernstein C.N. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am. J. Gastroenterol. 2003, 98:1064-1072.
2. Kang S.S., Bloom S.M., Norian L.A., Geske M.J., Flavell R.A., Stappenbeck T.S., Allen P.M. An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med. 2008, 5:e41.
3. Vucelic B. Inflammatory bowel diseases: controversies in the use of diagnostic procedures. Dig. Dis. 2009, 27:269-277.
4. Kaser A., Zeissig S., Blumberg R.S. Inflammatory bowel disease. Annu. Rev. Immunol. 2010, 28:573-621.
5. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 2006, 3:390-407.
6. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
7. Koboziev I., Karlsson F., Zhang S., Grisham M.B. Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies. Inflamm. Bowel Dis. 2011, 17:1229-1245.
8. Koboziev I., Webb C.R., Furr K.L., Grisham M.B. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic. Biol. Med. 2013, 68:122-133.
9. Chassaing B., Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1720-1728.
10. Ventham N.T., Kennedy N.A., Nimmo E.R., Satsangi J. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastroenterology 2013, 145:293-308.
11. Jostins L., Ripke S., Weersma R.K., Duerr R.H., McGovern D.P., Hui K.Y., Lee J.C., Schumm L.P., Sharma Y., Anderson C.A., Essers J., Mitrovic M., Ning K., Cleynen I., Theatre E., Spain S.L., Raychaudhuri S., Goyette P., Wei Z., Abraham C., Achkar J.P., Ahmad T., Amininejad L., Ananthakrishnan A.N., Andersen V., Andrews J.M., Baidoo L., Balschun T., Bampton P.A., Bitton A., Boucher G., Brand S., Buning C., Cohain A., Cichon S., D'Amato M., De Jong D., Devaney K.L., Dubinsky M., Edwards C., Ellinghaus D., Ferguson L.R., Franchimont D., Fransen K., Gearry R., Georges M., Gieger C., Glas J., Haritunians T., Hart A., Hawkey C., Hedl M., Hu X., Karlsen T.H., Kupcinskas L., Kugathasan S., Latiano A., Laukens D., Lawrance I.C., Lees C.W., Louis E., Mahy G., Mansfield J., Morgan A.R., Mowat C., Newman W., Palmieri O., Ponsioen C.Y., Potocnik U., Prescott N.J., Regueiro M., Rotter J.I., Russell R.K., Sanderson J.D., Sans M., Satsangi J., Schreiber S., Simms L.A., Sventoraityte J., Targan S.R., Taylor K.D., Tremelling M., Verspaget H.W., De Vos M., Wijmenga C., Wilson D.C., Winkelmann J., Xavier R.J., Zeissig S., Zhang B., Zhang C.K., Zhao H., Silverberg M.S., Annese V., Hakonarson H., Brant S.R., Radford-Smith G., Mathew C.G., Rioux J.D., Schadt E.E., Daly M.J., Franke A., Parkes M., Vermeire S., Barrett J.C., Cho J.H. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491:119-124.
12. Bernstein C.N., Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut 2008, 57:1185-1191.
13. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011, 140:1785-1794.
14. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317.
15. Molodecky N.A., Soon I.S., Rabi D.M., Ghali W.A., Ferris M., Chernoff G., Benchimol E.I., Panaccione R., Ghosh S., Barkema H.W., Kaplan G.G. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142:46-54.
16. Manichanh C., Borruel N., Casellas F., Guarner F. The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:599-608.
17. Spor A., Koren O., Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat. Rev. Microbiol. 2011, 9:279-290.
18. Coombes J.L., Robinson N.J., Maloy K.J., Uhlig H.H., Powrie F. Regulatory T cells and intestinal homeostasis. Immunol. Rev. 2005, 204:184-194.
19. Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu. Rev. Immunol. 2009, 27:313-338.
20. Manichanh C., Rigottier-Gois L., Bonnaud E., Gloux K., Pelletier E., Frangeul L., Nalin R., Jarrin C., Chardon P., Marteau P., Roca J., Dore J. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 2006, 55:205-211.
21. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host. Microbe 2008, 3:417-427.
22. Rehman A., Lepage P., Nolte A., Hellmig S., Schreiber S., Ott S.J. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J. Med. Microbiol. 2010, 59:1114-1122.
23. Sokol H., Pigneur B., Watterlot L., Lakhdari O., Bermudez-Humaran L.G., Gratadoux J.J., Blugeon S., Bridonneau C., Furet J.P., Corthier G., Grangette C., Vasquez N., Pochart P., Trugnan G., Thomas G., Blottiere H.M., Dore J., Marteau P., Seksik P., Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:16731-16736.
24. Mazmanian S.K., Liu C.H., Tzianabos A.O., Kasper D.L. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122:107-118.
25. Mazmanian S.K., Round J.L., Kasper D.L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008, 453:620-625.
26. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:13780-13785.
27. Mukhopadhya I., Hansen R., El-Omar E.M., Hold G.L. IBD-what role do Proteobacteria play?. Nat. Rev. Gastroenterol. Hepatol. 2012, 9:219-230.
28. Willing B.P., Dicksved J., Halfvarson J., Andersson A.F., Lucio M., Zheng Z., Jarnerot G., Tysk C., Jansson J.K., Engstrand L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010, 139:1844-1854.
29. Martinez-Medina M., Aldeguer X., Lopez-Siles M., Gonzalez-Huix F., Lopez-Oliu C., Dahbi G., Blanco J.E., Blanco J., Garcia-Gil L.J., Darfeuille-Michaud A. Molecular diversity of Escherichia coli in the human gut: new ecological evidence supporting the role of adherent-invasive E. coli (AIEC) in Crohn's disease. Inflamm. Bowel Dis. 2009, 15:872-882.
30. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 2003, 3:745-756.
31. Feller M., Huwiler K., Schoepfer A., Shang A., Furrer H., Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect. Dis. 2010, 50:473-480.
32. Preidis G.A., Versalovic J. Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. Gastroenterology 2009, 136:2015-2031.
33. Walker A.W., Lawley T.D. Therapeutic modulation of intestinal dysbiosis. Pharmacol. Res. 2013, 69:75-86.
34. Joossens M., Huys G., Cnockaert M., De P.V., Verbeke K., Rutgeerts P., Vandamme P., Vermeire S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011, 60:631-637.
35. Lupp C., Robertson M.L., Wickham M.E., Sekirov I., Champion O.L., Gaynor E.C., Finlay B.B. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host. Microbe 2007, 2:204.
36. Kirsner J.B., Elchlepp J. The production of an experimental ulcerative colitis in rabbits. Trans. Assoc. Am. Physicians 1957, 70:102-119.
37. Kirsner J.B., Elchlepp J.G., Goldgraber M.B., Ablaza J., Ford H. Production of an experimental ulcerative "colitis" in rabbits. Arch. Pathol. 1959, 68:392-408.
38. Kraft S.C., Fitch F.W., Kirsner J.B. Histologic and immunohistochemical features of the auer "colitis" in rabbits. Am. J. Pathol. 1963, 43:913-927.
39. Kitajima S., Morimoto M., Sagara E., Shimizu C., Ikeda Y. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp. Anim. 2001, 50:387-395.
40. Mombaerts P., Mizoguchi E., Grusby M.J., Glimcher L.H., Bhan A.K., Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 1993, 75:274-282.
41. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
42. Powrie F., Leach M.W., Mauze S., Caddle L.B., Coffman R.L. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int. Immunol. 1993, 5:1461-1471.
43. Elson C.O. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol. Rev. 2005, 206:260-276.
44. Maxwell J.R., Viney J.L. Overview of mouse models of inflammatory bowel disease and their use in drug discovery. Curr. Protoc. Pharmacol. 2009, 47. 5.57.51-55.57.19.
45. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 2007, 117:514-521.
46. Strober W., Fuss I.J., Blumberg R.S. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 2002, 20:495-549.
47. Uhlig H.H., Powrie F. Mouse models of intestinal inflammation as tools to understand the pathogenesis of inflammatory bowel disease. Eur. J. Immunol. 2009, 39:2021-2026.
48. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
49. DeVoss J., Diehl L. Murine models of inflammatory bowel disease (IBD): challenges of modeling human disease. Toxicol. Pathol. 2014, 42:99-110.
50. Podolsky D.K. Inflammatory bowel disease. N. Engl. J. Med. 2002, 347:417-429.
51. Head K.A., Jurenka J.S. Inflammatory bowel disease. Part 1: Ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 2003, 8:247-283.
52. Levine J.S., Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol. Hepatol. (N. Y.) 2011, 7:235-241.
53. Bamias G., Kaltsa G., Ladas S.D. Cytokines in the pathogenesis of ulcerative colitis. Discov. Med. 2011, 11:459-467.
54. Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2008, 14:390-400.
55. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3:521-533.
56. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52:65-70.
57. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br. Med. J. 1964, 1:89-92.
58. Nishimura M., Kuboi Y., Muramoto K., Kawano T., Imai T. Chemokines as novel therapeutic targets for inflammatory bowel disease. Ann. N. Y. Acad. Sci. 2009, 1173:350-356.
59. Nahon S., Bouhnik Y., Lavergne-Slove A., Bitoun A., Panis Y., Valleur P., Vahedi K., Messing B., Matuchansky C., Rambaud J.C. Colonoscopy accurately predicts the anatomical severity of colonic Crohn's disease attacks: correlation with findings from colectomy specimens. Am. J. Gastroenterol. 2002, 97:3102-3107.
60. Bernstein C.N., Blanchard J.F., Rawsthorne P., Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 2001, 96:1116-1122.
61. Levine J.B., Lukawski-Trubish D. Extraintestinal considerations in inflammatory bowel disease. Gastroenterol. Clin. North Am. 1995, 24:633-646.
62. Asquith P., Thompson R.A., Cooke W.T. Oral manifestations of Crohn's disease. Gut 1975, 16:249-254.
63. Pittock S., Drumm B., Fleming P., McDermott M., Imrie C., Flint S., Bourke B. The oral cavity in Crohn's disease. J. Pediatr. 2001, 138:767-771.
64. Yamamoto K., Kiyohara T., Murayama Y., Kihara S., Okamoto Y., Funahashi T., Ito T., Nezu R., Tsutsui S., Miyagawa J.I., Tamura S., Matsuzawa Y., Shimomura I., Shinomura Y. Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. Gut 2005, 54:789-796.
65. Paul G., Schaffler A., Neumeier M., Furst A., Bataillle F., Buechler C., Muller-Ladner U., Scholmerich J., Rogler G., Herfarth H. Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm. Bowel Dis. 2006, 12:471-477.
66. Bentley E., Jenkins D., Campbell F., Warren B. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J. Clin. Pathol. 2002, 55:955-960.
67. Strober W. Animal models of inflammatory bowel disease - an overview. Dig. Dis. Sci. 1985, 30:3S-10S.
68. Stepankova R., Powrie F., Kofronova O., Kozakova H., Hudcovic T., Hrncir T., Uhlig H., Read S., Rehakova Z., Benada O., Heczko P., Strus M., Bland P., Tlaskalova-Hogenova H. Segmented filamentous bacteria in a defined bacterial cocktail induce intestinal inflammation in SCID mice reconstituted with CD45RBhigh CD4+ T cells. Inflamm. Bowel Dis. 2007, 13:1202-1211.
69. Matsumoto S., Watanabe N., Imaoka A., Okabe Y. Preventive effects of Bifidobacterium- and Lactobacillus-fermented milk on the development of inflammatory bowel disease in senescence-accelerated mouse P1/Yit strain mice. Digestion 2001, 64:92-99.
70. Rivera-Nieves J., Bamias G., Vidrich A., Marini M., Pizarro T.T., McDuffie M.J., Moskaluk C.A., Cohn S.M., Cominelli F. Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis. Gastroenterology 2003, 124:972-982.
71. Skeen M.J., Miller M.A., Shinnick T.M., Ziegler H.K. Regulation of murine macrophage IL-12 production. Activation of macrophages in vivo, restimulation in vitro, and modulation by other cytokines. J. Immunol. 1996, 156:1196-1206.
72. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993, 178:1041-1048.
73. Ohkusa T. [Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora]. Nihon Shokakibyo Gakkai Zasshi 1985, 82:1327-1336.
74. Awasthi A., Carrier Y., Peron J.P., Bettelli E., Kamanaka M., Flavell R.A., Kuchroo V.K., Oukka M., Weiner H.L. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat. Immunol. 2007, 8:1380-1389.
75. Weaver C.T., Harrington L.E., Mangan P.R., Gavrieli M., Murphy K.M. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006, 24:677-688.
76. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 2007, 8:191-197.
77. Kuhn R., Lohler J., Rennick D., Rajewsky K., Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993, 75:263-274.
78. Mahler M., Leiter E.H. Genetic and environmental context determines the course of colitis developing in IL-10-deficient mice. Inflamm. Bowel Dis. 2002, 8:347-355.
79. Ward J.M., Anver M.R., Haines D.C., Melhorn J.M., Gorelick P., Yan L., Fox J.G. Inflammatory large bowel disease in immunodeficient mice naturally infected with Helicobacter hepaticus. Lab. Anim. Sci. 1996, 46:15-20.
80. Balish E., Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am. J. Pathol. 2002, 160:2253-2257.
81. Chichlowski M., Sharp J.M., Vanderford D.A., Myles M.H., Hale L.P. Helicobacter typhlonius and Helicobacter rodentium differentially affect the severity of colon inflammation and inflammation-associated neoplasia in IL10-deficient mice. Comp. Med. 2008, 58:534-541.
82. Hoshi N., Schenten D., Nish S.A., Walther Z., Gagliani N., Flavell R.A., Reizis B., Shen Z., Fox J.G., Iwasaki A., Medzhitov R. MyD88 signalling in colonic mononuclear phagocytes drives colitis in IL-10-deficient mice. Nat. Commun. 2012, 3:1120.
83. Gazzinelli R.T., Wysocka M., Hieny S., Scharton-Kersten T., Cheever A., Kuhn R., Muller W., Trinchieri G., Sher A. In the absence of endogenous IL-10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accompanied by overproduction of IL-12, IFN-gamma and TNF-alpha. J. Immunol. 1996, 157:798-805.
84. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., Thompson-Snipes L., Leach M.W., Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J. Clin. Invest. 1996, 98:1010-1020.
85. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U. S. A. 1975, 72:3666-3670.
86. Vandenabeele P., Declercq W., Beyaert R., Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995, 5:392-399.
87. Gaur U., Aggarwal B.B. Regulation of proliferation, survival and apoptosis by members of the TNF superfamily. Biochem. Pharmacol. 2003, 66:1403-1408.
88. Caput D., Beutler B., Hartog K., Thayer R., Brown-Shimer S., Cerami A. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. U. S. A. 1986, 83:1670-1674.
89. Han J., Brown T., Beutler B. Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translational level. J. Exp. Med. 1990, 171:465-475.
90. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999, 10:387-398.
91. Pizarro T.T., Arseneau K.O., Bamias G., Cominelli F. Mouse models for the study of Crohn's disease. Trends Mol. Med. 2003, 9:218-222.
92. Kontoyiannis D., Boulougouris G., Manoloukos M., Armaka M., Apostolaki M., Pizarro T., Kotlyarov A., Forster I., Flavell R., Gaestel M., Tsichlis P., Cominelli F., Kollias G. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J. Exp. Med. 2002, 196:1563-1574.
93. Pizarro T.T., Arseneau K.O., Cominelli F. Lessons from genetically engineered animal models: XI. Novel mouse models to study pathogenic mechanisms of Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278:G665-G669.
94. Werner T., Wagner S.J., Martinez I., Walter J., Chang J.S., Clavel T., Kisling S., Schuemann K., Haller D. Depletion of luminal iron alters the gut microbiota and prevents Crohn's disease-like ileitis. Gut 2011, 60:325-333.
95. Buning J., von Smolinski D., Tafazzoli K., Zimmer K.P., Strobel S., Apostolaki M., Kollias G., Heath J.K., Ludwig D., Gebert A. Multivesicular bodies in intestinal epithelial cells: responsible for MHC class II-restricted antigen processing and origin of exosomes. Immunology 2008, 125:510-521.
96. Lala S., Ogura Y., Osborne C., Hor S.Y., Bromfield A., Davies S., Ogunbiyi O., Nunez G., Keshav S. Crohn's disease and the NOD2 gene: a role for paneth cells. Gastroenterology 2003, 125:47-57.
97. Roulis M., Armaka M., Manoloukos M., Apostolaki M., Kollias G. Intestinal epithelial cells as producers but not targets of chronic TNF suffice to cause murine Crohn-like pathology. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:5396-5401.
98. Bamias G., Dahman M.I., Arseneau K.O., Guanzon M., Gruska D., Pizarro T.T., Cominelli F. Intestinal-specific TNFalpha overexpression induces Crohn's-like ileitis in mice. PLOS ONE 2013, 8:e72594.
99. Ostanin D.V., Bao J., Koboziev I., Gray L., Robinson-Jackson S.A., Kosloski-Davidson M., Price V.H., Grisham M.B. T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G135-G146.
100. Ostanin D.V., Pavlick K.P., Bharwani S., D'Souza D., Furr K.L., Brown C.M., Grisham M.B. T cell-induced inflammation of the small and large intestine in immunodeficient mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290:G109-G119.
101. Powrie F. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity 1995, 3:171-174.
102. Barnes M.J., Powrie F. Regulatory T cells reinforce intestinal homeostasis. Immunity 2009, 31:401-411.
103. +CD45RBhigh T lymphocytes into nude mice. Inflamm. Bowel Dis. 2006, 12:89-99.
104. Mizoguchi A., Mizoguchi E., Takedatsu H., Blumberg R.S., Bhan A.K. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002, 16:219-230.
105. Mizoguchi E., Mizoguchi A., Preffer F.I., Bhan A.K. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int. Immunol. 2000, 12:597-605.
106. Hagenbaugh A., Sharma S., Dubinett S.M., Wei S.H., Aranda R., Cheroutre H., Fowell D.J., Binder S., Tsao B., Locksley R.M., Moore K.W., Kronenberg M. Altered immune responses in interleukin 10 transgenic mice. J. Exp. Med. 1997, 185:2101-2110.
107. Murai M., Turovskaya O., Kim G., Madan R., Karp C.L., Cheroutre H., Kronenberg M. Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat. Immunol. 2009, 10:1178-1184.
108. Dohi T., Fujihashi K., Koga T., Shirai Y., Kawamura Y.I., Ejima C., Kato R., Saitoh K., McGhee J.R. T helper type-2 cells induce ileal villus atrophy, goblet cell metaplasia, and wasting disease in T cell-deficient mice. Gastroenterology 2003, 124:672-682.
109. +CD45RBHi interleukin-4 defective T cells elicit antral gastritis and duodenitis. Am. J. Pathol. 2004, 165:1257-1268.
110. Nemoto Y., Kanai T., Takahara M., Oshima S., Okamoto R., Tsuchiya K., Matsumoto S., Watanabe M. Th1/Th17-mediated interstitial pneumonia in chronic colitis mice independent of intestinal microbiota. J. Immunol. 2013, 190:6616-6625.
111. Aranda R., Sydora B.C., McAllister P.L., Binder S.W., Yang H.Y., Targan S.R., Kronenberg M. Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J. Immunol. 1997, 158:3464-3473.
112. Jiang H.Q., Kushnir N., Thurnheer M.C., Bos N.A., Cebra J.J. Monoassociation of SCID mice with Helicobacter muridarum, but not four other enterics, provokes IBD upon receipt of T cells. Gastroenterology 2002, 122:1346-1354.
113. O'Connor W., Kamanaka M., Booth C.J., Town T., Nakae S., Iwakura Y., Kolls J.K., Flavell R.A. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 2009, 10:603-609.
114. + regulatory T cells suppress Th17-responses in an experimental colitis model. Dig. Dis. Sci. 2011, 56:376-386.
115. Ogino H., Nakamura K., Iwasa T., Ihara E., Akiho H., Motomura Y., Akahoshi K., Igarashi H., Kato M., Kotoh K., Ito T., Takayanagi R. Regulatory T cells expanded by rapamycin in vitro suppress colitis in an experimental mouse model. J. Gastroenterol. 2012, 47:366-376.
116. te Velde A.A., de Kort F., Sterrenburg E., Pronk I., ten Kate F.J., Hommes D.W., van Deventer S.J. Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm. Bowel Dis. 2007, 13:325-330.
117. Takeda T., Hosokawa M., Takeshita S., Irino M., Higuchi K., Matsushita T., Tomita Y., Yasuhira K., Hamamoto H., Shimizu K., Ishii M., Yamamuro T. A new murine model of accelerated senescence. Mech. Ageing Dev. 1981, 17:183-194.
118. Matsumoto S., Okabe Y., Setoyama H., Takayama K., Ohtsuka J., Funahashi H., Imaoka A., Okada Y., Umesaki Y. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998, 43:71-78.
119. Kosiewicz M.M., Nast C.C., Krishnan A., Rivera-Nieves J., Moskaluk C.A., Matsumoto S., Kozaiwa K., Cominelli F. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J. Clin. Invest. 2001, 107:695-702.
120. Bamias G., Okazawa A., Rivera-Nieves J., Arseneau K.O., De La Rue S.A., Pizarro T.T., Cominelli F. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J. Immunol. 2007, 178:1809-1818.
121. Bamias G., Marini M., Moskaluk C.A., Odashima M., Ross W.G., Rivera-Nieves J., Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 2002, 169:5308-5314.
122. Pagnini C., Saeed R., Bamias G., Arseneau K.O., Pizarro T.T., Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:454-459.
123. Reuter B.K., Pastorelli L., Brogi M., Garg R.R., McBride J.A., Rowlett R.M., Arrieta M.C., Wang X.M., Keller E.J., Feldman S.H., Mize J.R., Cominelli F., Meddings J.B., Pizarro T.T. Spontaneous, immune-mediated gastric inflammation in SAMP1/YitFc mice, a model of Crohn's-like gastritis. Gastroenterology 2011, 141:1709-1719.
124. Miller A.M. Role of IL-33 in inflammation and disease. J. Inflamm. (Lond.) 2011, 8:22.
125. Pastorelli L., Garg R.R., Hoang S.B., Spina L., Mattioli B., Scarpa M., Fiocchi C., Vecchi M., Pizarro T.T. Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:8017-8022.
126. Bamias G., Martin C., Mishina M., Ross W.G., Rivera-Nieves J., Marini M., Cominelli F. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005, 128:654-666.
127. Takedatsu H., Mitsuyama K., Matsumoto S., Handa K., Suzuki A., Funabashi H., Okabe Y., Hara T., Toyonaga A., Sata M. Interleukin-5 participates in the pathogenesis of ileitis in SAMP1/Yit mice. Eur. J. Immunol. 2004, 34:1561-1569.
128. Kimura I., Nagahama S., Kawasaki M., Kamiya A., Kataoka M. Study on the experimental ulcerative colitis (UC) model induced by dextran sulfate sodium (DSS) in rats (2). Nihon Yakurigaku Zasshi 1995, 105:145-152.
129. Iwanaga T., Hoshi O., Han H., Fujita T. Morphological analysis of acute ulcerative colitis experimentally induced by dextran sulfate sodium in the guinea pig: some possible mechanisms of cecal ulceration. J. Gastroenterol. 1994, 29:430-438.
130. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
131. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 1993, 69:238-249.
132. Dieleman L.A., Ridwan B.U., Tennyson G.S., Beagley K.W., Bucy R.P., Elson C.O. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994, 107:1643-1652.
133. Krieglstein C.F., Cerwinka W.H., Sprague A.G., Laroux F.S., Grisham M.B., Koteliansky V.E., Senninger N., Granger D.N., de Fougerolles A.R. Collagen-binding integrin alpha1beta1 regulates intestinal inflammation in experimental colitis. J. Clin. Invest. 2002, 110:1773-1782.
134. Axelsson L.G., Landstrom E., Goldschmidt T.J., Gronberg A., Bylund-Fellenius A.C. Dextran sulfate sodium (DSS) induced experimental colitis in immunodeficient mice: effects in CD4(+)-cell depleted, athymic and NK-cell depleted SCID mice. Inflamm. Res. 1996, 45:181-191.
135. Morgan M.E., Zheng B., Koelink P.J., van de Kant H.J., Haazen L.C., van Roest M., Garssen J., Folkerts G., Kraneveld A.D. New perspective on dextran sodium sulfate colitis: antigen-specific T cell development during intestinal inflammation. PLOS ONE 2013, 8:e69936.
136. Kitajima S., Takuma S., Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp. Anim. 1999, 48:137-143.
137. Hall L.J., Faivre E., Quinlan A., Shanahan F., Nally K., Melgar S. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig. Dis. Sci. 2011, 56:79-89.
138. B.I Mähler M., Leiter E.H., Workman A.E., Birkenmeier E.H., Elson C.O., Sundberg J.P. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am. J. Physiol. 1998, 274:G544-G551.
139. Melgar S., Karlsson A., Michaelsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1328-G1338.
140. Wirtz S., Neufert C., Weigmann B., Neurath M.F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2:541-546.
141. Kitajima S., Takuma S., Morimoto M. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp. Anim. 2000, 49:9-15.
142. Alex P., Zachos N.C., Nguyen T., Gonzales L., Chen T.E., Conklin L.S., Centola M., Li X. Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 2009, 15:341-352.
143. Seno H., Miyoshi H., Brown S.L., Geske M.J., Colonna M., Stappenbeck T.S. Efficient colonic mucosal wound repair requires Trem2 signaling. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:256-261.
144. Mills C.D. M1 and M2 macrophages: oracles of health and disease. Crit. Rev. Immunol. 2012, 32:463-488.
145. Yang X., Gartner J., Zhu L., Wang S., Brunham R.C. IL-10 gene knockout mice show enhanced Th1-like protective immunity and absent granuloma formation following Chlamydia trachomatis lung infection. J. Immunol. 1999, 162:1010-1017.
146. Fukata M., Michelsen K.S., Eri R., Thomas L.S., Hu B., Lukasek K., Nast C.C., Lechago J., Xu R., Naiki Y., Soliman A., Arditi M., Abreu M.T. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1055-G1065.
147. Hans W., Scholmerich J., Gross V., Falk W. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur. J. Gastroenterol. Hepatol. 2000, 12:267-273.
148. Rakoff-Nahoum S., Paglino J., Eslami-Varzaneh F., Edberg S., Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004, 118:229-241.
149. Nanda Kumar N.S., Balamurugan R., Jayakanthan K., Pulimood A., Pugazhendhi S., Ramakrishna B.S. Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate. J. Gastroenterol. Hepatol. 2008, 23:1834-1839.
150. Verdu E.F., Bercik P., Cukrowska B., Farre-Castany M.A., Bouzourene H., Saraga E., Blum A.L., Corthesy-Theulaz I., Tlaskalova-Hogenova H., Michetti P. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin. Exp. Immunol. 2000, 120:46-50.
151. Pils M.C., Bleich A., Prinz I., Fasnacht N., Bollati-Fogolin M., Schippers A., Rozell B., Muller W. Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10. Inflamm. Bowel Dis. 2011, 17:2038-2046.
152. Matsumoto S., Hara T., Hori T., Mitsuyama K., Nagaoka M., Tomiyasu N., Suzuki A., Sata M. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin. Exp. Immunol. 2005, 140:417-426.
153. Araki A., Kanai T., Ishikura T., Makita S., Uraushihara K., Iiyama R., Totsuka T., Takeda K., Akira S., Watanabe M. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J. Gastroenterol. 2005, 40:16-23.
154. Chen Y., Chou K., Fuchs E., Havran W.L., Boismenu R. Protection of the intestinal mucosa by intraepithelial gamma delta T cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14338-14343.
155. Araki Y., Mukaisyo K., Sugihara H., Fujiyama Y., Hattori T. Increased apoptosis and decreased proliferation of colonic epithelium in dextran sulfate sodium-induced colitis in mice. Oncol. Rep. 2010, 24:869-874.
156. Solomon L., Mansor S., Mallon P., Donnelly E., Hoper M., Loughrey M., Kirk S., Gardiner K. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp. Clin. Pathol. 2010, 19:235-239.
157. Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 1991, 147:3815-3822.
158. Neurath M.F., Fuss I., Kelsall B.L., Stuber E., Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 1995, 182:1281-1290.
159. Brenna O., Furnes M.W., Drozdov I., van Beelen Granlund A., Flatberg A., Sandvik A.K., Zwiggelaar R.T., Marvik R., Nordrum I.S., Kidd M., Gustafsson B.I. Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and transcriptomic [corrected] characterization and correlation to IBD. PLOS ONE 2013, 8:e54543.
160. Neurath M.F., Pettersson S., Meyer zum Buschenfelde K.H., Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice. Nat. Med. 1996, 2:998-1004.
161. te Velde A.A., Verstege M.I., Hommes D.W. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm. Bowel Dis. 2006, 12:995-999.
162. Yamada Y., Marshall S., Specian R.D., Grisham M.B. A comparative analysis of two models of colitis in rats. Gastroenterology 1992, 102:1524-1534.
163. Grisham M.B., Volkmer C., Tso P., Yamada T. Metabolism of trinitrobenzene sulfonic acid by the rat colon produces reactive oxygen species. Gastroenterology 1991, 101:540-547.
164. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., Blumberg R.S., Serhan C.N. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:7671-7676.
165. Camoglio L., te Velde A.A., de Boer A., ten Kate F.J., Kopf M., van Deventer S.J. Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur. J. Immunol. 2000, 30:1486-1495.
166. Fichtner-Feigl S., Fuss I.J., Preiss J.C., Strober W., Kitani A. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J. Clin. Invest. 2005, 115:3057-3071.
167. Lawrance I.C., Wu F., Leite A.Z., Willis J., West G.A., Fiocchi C., Chakravarti S. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003, 125:1750-1761.
168. Fiorucci S., Mencarelli A., Palazzetti B., Sprague A.G., Distrutti E., Morelli A., Novobrantseva T.I., Cirino G., Koteliansky V.E., de Fougerolles A.R. Importance of innate immunity and collagen binding integrin alpha1beta1 in TNBS-induced colitis. Immunity 2002, 17:769-780.
169. van Lierop P.P., de Haar C., Lindenbergh-Kortleve D.J., Simons-Oosterhuis Y., van Rijt L.S., Lambrecht B.N., Escher J.C., Samsom J.N., Nieuwenhuis E.E. T-cell regulation of neutrophil infiltrate at the early stages of a murine colitis model. Inflamm. Bowel Dis. 2010, 16:442-451.
170. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J. Exp. Med. 1996, 183:2605-2616.
171. Scheiffele F., Fuss I.J. Induction of TNBS colitis in mice. Curr. Protoc. Immunol. 2002, Chapter 15: Unit 15.19.
172. Bouma G., Kaushiva A., Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 2002, 123:554-565.
173. Boirivant M., Amendola A., Butera A., Sanchez M., Xu L., Marinaro M., Kitani A., Di Giacinto C., Strober W., Fuss I.J. A transient breach in the epithelial barrier leads to regulatory T-cell generation and resistance to experimental colitis. Gastroenterology 2008, 135:1612-1623. e1615.
174. Duchmann R., Schmitt E., Knolle P., Meyer zum Buschenfelde K.H., Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 1996, 26:934-938.
175. Roselli M., Finamore A., Nuccitelli S., Carnevali P., Brigidi P., Vitali B., Nobili F., Rami R., Garaguso I., Mengheri E. Prevention of TNBS-induced colitis by different Lactobacillus and Bifidobacterium strains is associated with an expansion of γδT and regulatory T cells of intestinal intraepithelial lymphocytes. Inflamm. Bowel Dis. 2009, 15:1526-1536.
176. Mane J., Loren V., Pedrosa E., Ojanguren I., Xaus J., Cabre E., Domenech E., Gassull M.A. Lactobacillus fermentum CECT 5716 prevents and reverts intestinal damage on TNBS-induced colitis in mice. Inflamm. Bowel Dis. 2009, 15:1155-1163.
177. Treem W.R., Ahsan N., Shoup M., Hyams J.S. Fecal short-chain fatty acids in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 1994, 18:159-164.
178. Cherbut C., Michel C., Lecannu G. The prebiotic characteristics of fructooligosaccharides are necessary for reduction of TNBS-induced colitis in rats. J. Nutr. 2003, 133:21-27.
179. Maslowski K.M., Vieira A.T., Ng A., Kranich J., Sierro F., Yu D., Schilter H.C., Rolph M.S., Mackay F., Artis D., Xavier R.J., Teixeira M.M., Mackay C.R. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 2009, 461:1282-1286.
180. Kim M.H., Kang S.G., Park J.H., Yanagisawa M., Kim C.H. Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. Gastroenterology 2013, 145:396-406. e391-310.
181. Feng T., Wang L., Schoeb T.R., Elson C.O., Cong Y. Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J. Exp. Med. 2010, 207:1321-1332.
182. Powrie F., Read S., Mottet C., Uhlig H., Maloy K. Control of immune pathology by regulatory T cells. Novartis Found. Symp. 2003, 252:92-98.
183. Mestas J., Hughes C.C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 2004, 172:2731-2738.
184. Hackam D.G., Redelmeier D.A. Translation of research evidence from animals to humans. JAMA 2006, 296:1731-1732.
185. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V., Macleod M.R. Can animal models of disease reliably inform human studies?. PLoS. Med. 2010, 7:e1000245.
186. Valatas V., Vakas M., Kolios G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305:G763-G785.
187. NIH, N.I.o. Health, 2013. http://www.clinicaltrials.gov/.
188. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 2012, 12:786-798.
189. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
190. Brehm M.A., Shultz L.D., Greiner D.L. Humanized mouse models to study human diseases. Curr. Opin. Endocrinol. Diabetes Obes. 2010, 17:120-125.
191. Alaniz R., Shepherd T., Ryden K., Jia Q., Davidson L., Chapkin R. S25 humanized mouse model of inflammatory bowel disease and microbial immunity. J. Crohn's Colitis Suppl. 2010, 4:28.
192. Zhou C., Tabb M.M., Nelson E.L., Grun F., Verma S., Sadatrafiei A., Lin M., Mallick S., Forman B.M., Thummel K.E., Blumberg B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 2006, 116:2280-2289.
193. Langmann T., Moehle C., Mauerer R., Scharl M., Liebisch G., Zahn A., Stremmel W., Schmitz G. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004, 127:26-40.
194. Cheng J., Shah Y.M., Ma X., Pang X., Tanaka T., Kodama T., Krausz K.W., Gonzalez F.J. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation. J. Pharmacol. Exp. Ther. 2010, 335:32-41.
195. Winsauer C., Kruglov A.A., Chashchina A.A., Drutskaya M.S., Nedospasov S.A. Cellular sources of pathogenic and protective TNF and experimental strategies based on utilization of TNF humanized mice. Cytokine Growth Factor Rev. 2014, 25:115-123.